Summary NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (NRx, the Company, we, us or our) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc., (NeuroRx), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder (PTSD) and schizophrenia. NRx is additionally the founder and majority owner of HOPE Therapeutics, Inc. (HOPE), ...
Q2 FY2026 — expected 2026-09-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001437749-26-009418 | EDGAR | 96K words |
| 2025-03-14 | 2024-12-31 | 0001437749-25-007743 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001558370-24-004396 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001558370-23-005292 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001558370-22-004899 | EDGAR | — |
| 2021-04-01 | 2020-12-31 | 0001654954-21-003783 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001654954-20-003527 | EDGAR | — |
| 2019-03-15 | 2018-12-31 | 0001654954-19-002833 | EDGAR | — |
| 2018-03-23 | 2017-12-31 | 0001654954-18-003022 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001437749-25-035210 | EDGAR | 48K words |
| 2025-08-18 | 2025-06-30 | 0001437749-25-027167 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001437749-25-017252 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001437749-24-035289 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001437749-24-026847 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008144 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001558370-23-019008 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014873 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009950 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017772 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001558370-22-013673 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001558370-22-008948 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-24 | 0001437749-26-009611 | EDGAR | 1K words |
| 2026-02-17 | 0001437749-26-004246 | EDGAR | — |
| 2026-02-17 | 0001437749-26-004245 | EDGAR | — |
| 2026-02-02 | 0001437749-26-002682 | EDGAR | — |
| 2026-01-16 | 0001437749-26-001455 | EDGAR | — |
| 2025-12-29 | 0001437749-25-038835 | EDGAR | — |
| 2025-11-26 | 0001437749-25-036452 | EDGAR | — |
| 2025-10-23 | 0001437749-25-031637 | EDGAR | — |
| 2025-09-26 | 0001437749-25-029907 | EDGAR | — |
| 2025-09-12 | 0001437749-25-028949 | EDGAR | — |
207 total filings indexed. 176 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001719406 |
| Ticker | NRXP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://nrxpharma.com |
| Listed | 2021-05-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report